Infectious Disease Division, Azienda Sanitaria Universitaria Integrata, Presidio Ospedaliero Universitario Santa Maria della Misericordia.
Department of Medicine, Infectious Diseases Clinic, University of Udine, Udine, Italy.
Curr Opin Infect Dis. 2018 Apr;31(2):141-147. doi: 10.1097/QCO.0000000000000430.
The increase of skin and soft tissue infections (SSTIs) represents a major concern both in community and in the hospital setting. Staphylococcus aureus is the most frequently isolated pathogen, and the rise in infections due to methicillin-resistant Staphylococcus aureus (MRSA) has been associated with inadequate antibiotic treatment and increased morbidity.
A number of new antimicrobials with activity against drug-resistant Gram-positive pathogens, including MRSA, have been recently approved for the treatment of SSTIs. New lipoglycopeptides, in particular dalbavancin, are long-acting antibiotics with potential for infrequent administration, offering the possibility for outpatient treatment and early hospital discharge.
Dalbavancin is a new lipoglycopeptide showing high activity against Gram-positive bacteria, including drug-resistant strains. Dalbavancin presents a distinctive pharmacokinetic profile with a terminal prolonged half-life of approximately 14 days. This characteristic allows once-weekly dosing interval, avoiding the need for daily dosing and offering an advantage over other compounds for potential use in the outpatient setting or to promote early hospital discharge. Dalbavancin has a favorable adverse effect profile and appears to be a promising new alternative for treatment of SSTIs. We have reviewed the pharmacokinetic properties of dalbavancin and the clinical evidence for its use in complicated SSTIs and other potential applications.
皮肤和软组织感染（SSTIs）的增加，无论是在社区还是在医院环境中，都是一个主要关注点。金黄色葡萄球菌是最常分离到的病原体，耐甲氧西林金黄色葡萄球菌（MRSA）感染的增加与抗生素治疗不当和发病率增加有关。
一些新的抗菌药物具有针对耐药革兰阳性病原体（包括 MRSA）的活性，最近已被批准用于治疗 SSTIs。新型糖肽类药物，特别是达巴万星，是一种长效抗生素，潜在的给药频率较低，为门诊治疗和早期出院提供了可能。
达巴万星是一种新型糖肽类药物，对革兰阳性菌具有高活性，包括耐药菌株。达巴万星具有独特的药代动力学特征，终末半衰期约为 14 天，这一特征允许每周一次的给药间隔，避免了每日给药的需要，并为在门诊环境中或促进早期出院的潜在应用提供了优于其他化合物的优势。达巴万星具有良好的不良反应谱，似乎是治疗 SSTIs 的一种很有前途的新选择。我们回顾了达巴万星的药代动力学特性及其在复杂性 SSTIs 及其他潜在应用中的临床证据。
